Immunotherapy for Prostate Cancer
Table 1. Phase II Sipuleucel-T Combina on Studies
Trial
Na onal clinical
trial iden fier Status
a
Sipuleucel-T
and stereotac c
abla ve body
radia on (SABR)
NCT01818986
Single group assignment; Recrui ng;
Expected comple on date December 2020
APC8015 and
bevacizumab
NCT00027599
Single group assignment; Completed
Sipuleucel-T
with or without
tasquinimod
NCT02159950
Completed
Sequencing of
sipuleucel-T and
ADT
NCT01431391
Completed
Concurrent
vs. sequen al
sipuleucel-T and
abiraterone
NCT01487863 Completed
A study of
sipuleucel-T with
administra on of
enzalutamide
NCT01981122
Ac ve, not recrui ng; Expected comple on
date July 2017
Sipuleucel-T +
indoximod
NCT01560923 Ac ve, not recrui ng; Expected comple on
date November 2019
Sipuleucel-T
± RT
NCT01807065 Ac ve, not recrui ng; Expected comple on
date January 2019
Sipuleucel-T ±
pTVG-HP DNA
booster vaccine
NCT01706458 Completed
Sipuleucel-T ±
ipilimumab
NCT01804465 Recrui ng; Expected comple on date
December 2019
Sipuleucel-T ±
radium-223
NCT02463799 Recrui ng; Expected comple on date
December 2020
a
As determined by ClinicalTrials.gov. Accessed March 13, 2018
